Okthoba 2021: I-Cabozantinib (Cabometyx, Exelixis, Inc.) igunyazwe i-Food and Drug Administration kuziguli ezikhulile kanye nezingane ezineminyaka engu-12 ubudala nangaphezulu eziye zahlukanisa i-thyroi ethuthukisiwe endaweni noma ye-metastatic.
NgoJanuwari 14, 2019, i-cabozantinib (CABOMETYX, Exelixis, Inc.) yagunyazwa yi-Food and Drug Administration yeziguli ezine-hepatocellular carcinoma (HCC) ezike zelashwa nge-sorafenib ngaphambilini. I-appr..
Ngokuya ngocwaningo olushicilelwe kwiNew England Journal of Medicine olushicilelwe ngoJulayi 5, ukusinda kweCabozantinib okuphelele nokuqhubekayo ezigulini ezine-hepatocellular carcinoma kwakungcono kakhulu kune-p ..